High-Affinity CD25-Binding IL-2 Mutants Potently Stimulate Persistent T Cell Growth
- 14 July 2005
- journal article
- research article
- Published by American Chemical Society (ACS) in Biochemistry
- Vol. 44 (31) , 10696-10701
- https://doi.org/10.1021/bi050436x
Abstract
We have used directed evolution to construct IL-2 mutants that bind the IL-2 α receptor subunit (IL-2Rα, CD25) with affinities comparable to that of the IL-15−IL-15 α receptor subunit (IL-15Rα) interaction. T cells proliferate for up to 6 days following a 30 minute incubation with these IL-2 mutants, which may lead to potential applications for cancer and viral immunotherapy. Several alternative mechanisms have been proposed to explain the contrasting effects of IL-2 and IL-15 on T cell proliferation and death. These IL-2 mutants exhibit T cell growth response−receptor occupancy curves indistinguishable from that for IL-15, suggesting that much of the difference between wild-type IL-2 and IL-15 effects arises simply from their 1000-fold differing affinities for their private α receptor subunits.Keywords
This publication has 9 references indexed in Scilit:
- Control of T Cell ViabilityAnnual Review of Immunology, 2004
- Distinct pathways involving the FK506-binding proteins 12 and 12.6 underlie IL-2-versus IL-15-mediated proliferation of T cellsProceedings of the National Academy of Sciences, 2003
- Lymphocide: cytokines and the control of lymphoid homeostasisNature Reviews Immunology, 2002
- The IL-15Rα Chain Signals Through Association with Syk in Human B CellsThe Journal of Immunology, 2001
- Increased Endosomal Sorting of Ligand to Recycling Enhances Potency of an Interleukin-2 AnalogJournal of Biological Chemistry, 2000
- High-Dose Recombinant Interleukin 2 Therapy for Patients With Metastatic Melanoma: Analysis of 270 Patients Treated Between 1985 and 1993Journal of Clinical Oncology, 1999
- Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy.Journal of Clinical Oncology, 1995
- Pseudo-high affinity interleukin 2 (IL-2) receptor lacks the third component that is essential for functional IL-2 binding and signaling.The Journal of Experimental Medicine, 1992
- The interleukin 2 receptor.Annual Review of Cell Biology, 1989